Tonix Pharmaceuticals Holding Corp.
Novel small-molecule and biologic therapeutics and vaccines for CNS disorders, immunology, infectious diseases, and rare diseases
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2008
- Latest Form D
- $315K, Oct 2017
- Total capital
- $9.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $9.3M
- 5 Form D · last Oct 2017
- 109 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 20 pending · first 2022
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$315K
- Private capital raisedForm D · SEC · 4th filing$2.3M
- Private capital raisedForm D · SEC · 3rd filing$710K
- Private capital raisedForm D · SEC · 2nd filing$4.3M
- Private capital raisedForm D · SEC · 1st filing$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Seth LedermanResearcherExecutive Officer, DirectorLinked by 2 patents
- Benjamin SelzerExecutive OfficerNamed in SEC Form D filings
- Bradley SaengerExecutive OfficerNamed in SEC Form D filings
- Bruce DaughertyExecutive OfficerNamed in SEC Form D filings
- Charles MatherDirectorNamed in SEC Form D filings
- Charles E. Mather IVDirectorNamed in SEC Form D filings
Show all 18 people
- David MossDirectorNamed in SEC Form D filings
- Donald W. LandryDirectorNamed in SEC Form D filings
- Ernest W. MarioDirectorNamed in SEC Form D filings
- Gregory SullivanExecutive OfficerNamed in SEC Form D filings
- John RhodesDirectorNamed in SEC Form D filings
- Leland GershellExecutive OfficerNamed in SEC Form D filings
- Margaret Smith BellDirectorNamed in SEC Form D filings
- Patrick GraceDirectorNamed in SEC Form D filings
- Rhonda RosenExecutive OfficerNamed in SEC Form D filings
- Samuel SaksDirectorNamed in SEC Form D filings
- Stuart DavidsonDirectorNamed in SEC Form D filings
- Susan KerridgeExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 24- PendingEarly Onset Response, Favorable Tolerability, And Side Effect Profile In The Treatment Of FibromyalgiaUSPTOApplication 18988194
- PendingAnalogs Of Cyclobenzaprine And AmitryptileneUSPTOApplication 18950382
- GrantedAnalogs Of Cyclobenzaprine And AmitryptileneUSPTOUS 12,156,864
Show all 24 patent records
- Early Onset Response, Favorable Tolerability, And Side Effect Profile In The Treatment Of FibromyalgiaOct 16, 2025 · Application 18988194Pending
- Analogs Of Cyclobenzaprine And AmitryptileneMar 6, 2025 · Application 18950382Pending
- Analogs Of Cyclobenzaprine And AmitryptileneDec 3, 2024 · US 12,156,864Granted
- Radio-and Chemo-protective CompoundsJun 8, 2023 · Application 17923831Pending
- Radio-protective And Chemo-protective Substituted ThiolsMay 4, 2023 · Application 17991292Pending
- Radio-protective And Chemo-protective Substituted ThiolsJan 31, 2023 · US 11,566,032Granted
- Analogs Of Cyclobenzaprine And AmitryptileneDec 6, 2022 · US 11,517,557Granted
- Magnesium-containing Oxytocin Formulations And Methods Of UseJul 19, 2022 · US 11,389,473Granted
- Inhibitors Of CD40-CD154 BindingJun 16, 2022 · Application 17603260Pending
- Salts And Polymorphs Of EsreboxetineJun 20, 2019 · Application 15833973Pending
- Cyclobenzaprine Treatment For Alcohol Use DisorderApplication PCTUS2021060011Pending
- Inhibitors Of CD40-CD154 BindingApplication PCTUS2020028002Pending
- Analogs Of Cyclobenzaprine And AmitryptileneApplication PCTUS2018042184Pending
- Salts And Polymorphs Of EsreboxetineApplication PCTUS2017064944Pending
- CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)Application 63354215Pending
- Oxytocin Peptide AnalogsApplication 63566711Pending
- Cyclobenzaprine Treatment For Acute Stress Reaction Or Acute Stress DisorderApplication 63625257Pending
- Favorable Tolerability And Side Effect Profile In The Treatment Of FibromyalgiaApplication 63618892Pending
- Early Onset Response In The Treatment Of FibromyalgiaApplication 63612352Pending
- Recombinant Poxvirus Based Vaccine Against The Omicron Strain Of SARS-COV-2 Virus And Variants ThereofApplication PCTUS2023063503Pending
- Cyclobenzaprine Treatment For Sexual DysfunctionApplication PCTUS2022045791Pending
- Oxytocin Peptide AnalogsApplication PCTUS2025020483Pending
- RECOMBINANT POXVIRUS BASED VACCINE AGAINST THE OMICRON STRAIN OF SARS-CoV-2 VIRUS AND VARIANTS THEREOFApplication 63315520Pending
- Cyclobenzaprine Treatment For FibromyalgiaApplication PCTUS2021062244Pending
Related companies, and why
- Expanesthetics, IncSimilar federal contract value in Biotech · null in contracts
- Manistee Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ORIGIN, LLCSimilar federal contract value in Biotech · null in contracts
- Duke Street Bio LtdSimilar federal contract value in Biotech · null in contracts
- New Frontier Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Lattice Biologics Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .